NASHIK, India, May 21, 2026
Datar Cancer Genetics (DCG) has achieved a major milestone in precision oncology after receiving U.S. Food and Drug Administration (FDA) approval for CellDx-Tissue, its advanced comprehensive genomic profiling (CGP) assay designed for solid tumors using integrated DNA and RNA next-generation sequencing (NGS) technology. The approval significantly strengthens DCG’s position in the rapidly expanding global molecular diagnostics and precision cancer care market while reinforcing the increasing role of genomic profiling in personalized oncology treatment strategies. The FDA-approved assay evaluates 517 cancer-associated genes and is designed to help oncologists identify clinically actionable genomic alterations that can support treatment selection and long-term disease management across multiple solid tumor types.
The regulatory milestone represents a major advancement for India-origin biotechnology innovation and highlights the growing international recognition of AI-driven genomic diagnostics in modern cancer care. Datar Cancer Genetics stated that the FDA authorization validates the company’s scientific rigor, quality systems, and commitment to advancing personalized medicine solutions for cancer patients worldwide.
CellDx-Tissue Expands Precision Oncology Capabilities
According to Datar Cancer Genetics, CellDx-Tissue is a qualitative in vitro diagnostic (IVD) assay utilizing targeted next-generation sequencing of both DNA and RNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from patients diagnosed with solid tumors. The assay enables detection of clinically significant genomic abnormalities, including single nucleotide variants (SNVs), insertions and deletions (InDels), ERBB2 gene amplification, and gene fusions involving ALK, RET, and ROS1.
The assay is performed at Datar Cancer Genetics’ CAP- and CLIA-accredited laboratory, supporting standardized high-quality genomic testing and precision oncology workflows. Company officials noted that comprehensive genomic characterization has become a central component of cancer management because it allows physicians to better understand tumor biology and align patients with targeted therapies, biomarker-guided treatments, and personalized clinical strategies.
Advertisement
The FDA approval process involved rigorous review across analytical validation, clinical performance, quality systems, and information technology infrastructure, reflecting the high regulatory standards required for advanced genomic diagnostic platforms in the United States.
Dr. Vineet Datta, Senior Director – Global Strategy and Business Development at Datar Cancer Genetics, stated that the FDA approval provides prestigious regulatory recognition for CellDx-Tissue and reinforces the company’s mission to bridge the gap between genomic complexity and real-world clinical decision-making. He emphasized that the technology is intended to expand treatment options for cancer patients while helping oncologists navigate the rapidly evolving landscape of precision medicine and targeted therapies.
FDA Approval Strengthens Global Cancer Diagnostic Expansion
The approval is expected to significantly enhance DCG’s ability to collaborate with international hospitals, oncology centers, academic institutions, and biopharmaceutical companies on translational research, biomarker discovery, and companion diagnostic programs. The company believes the authorization will accelerate global adoption of its precision oncology technologies while strengthening its role in advanced cancer diagnostics and personalized medicine development.
Dr. Darshana Patil, Senior Director – Group Medical Affairs, described the approval as substantial validation of the company’s science and quality systems, enabling oncologists to access standardized genomic information for complex treatment decisions. She emphasized that the company remains committed to combining advanced genomics, rigorous science, and clinically relevant applications capable of improving patient outcomes globally.
Datar Cancer Genetics also highlighted its expanding international footprint across the United States, United Kingdom, European Union, Gulf Cooperation Council, and Asia, where the company continues developing tissue-based and liquid biopsy diagnostic platforms for cancer detection and monitoring. The company previously received FDA Breakthrough Device Designations for several liquid biopsy technologies, further strengthening its position within the fast-growing precision oncology sector.
Genomic Diagnostics Continue Transforming Cancer Care
Industry experts continue to identify comprehensive genomic profiling as one of the most transformative technologies in oncology because it enables clinicians to identify tumor-specific molecular drivers and guide patients toward targeted treatment options more effectively. As precision medicine adoption accelerates globally, demand for advanced genomic testing platforms capable of delivering clinically actionable insights continues rising across hospitals, cancer centers, and pharmaceutical research organizations.
The FDA approval of CellDx-Tissue further demonstrates the growing importance of integrating AI-driven diagnostics, molecular pathology, and next-generation sequencing technologies into mainstream cancer management workflows. Datar Cancer Genetics’ latest regulatory achievement positions the company among a new generation of global biotechnology innovators helping shape the future of personalized oncology care through advanced molecular diagnostics and precision medicine technologies.
Source: Datar Cancer Genetics press release
